Cardiva Medical, Inc. Announces Appointment of Randy Hubbell, Chief Commercial Officer

SUNNYVALE, Calif., Jan. 20, 2014 /PRNewswire/ -- Cardiva Medical, Inc. announced today that Randy Hubbell has been appointed Chief Commercial Officer. He will be responsible for expanding commercialization efforts for Cardiva's portfolio of devices for femoral vascular closure including the VASCADE® Vascular Closure System and the Catalyst® closure wire.

"Randy brings to Cardiva a unique blend of commercial expertise and strategic marketing that will prove invaluable to establishing Cardiva's technology as the new standard of care," said Charles Maroney, Cardiva President and CEO, "We are confident in Randy's ability to lead us to that goal."

Mr. Hubbell has over 20 years of sales and strategic marketing experience in the medical device business. Prior to joining Cardiva, Randy served as a senior sales and marketing executive at Johnson & Johnson for 14 years. He was Vice President, Worldwide Marketing at Ethicon Biosurgery from 2008 to 2013, where he was responsible for the global commercialization of hemostasis and surgical sealant products. Before that, he was Worldwide Vice President in the Pharmaceuticals Group Strategic Marketing. Randy joined Johnson & Johnson Cordis in 2001 as Director, US Stent Marketing, and was responsible for launching the 1^st drug-eluting stent, CYPHER. Before Johnson & Johnson, Randy was Vice President of Sales and Marketing at Enmed and Director of Sales and Marketing at NxStage. He began his career in medical devices at Boston Scientific. He holds a B.S. in Computer Science from Tulane University and an M.B.A. from Loyola University of the South.

Mr. Hubbell commented, "I believe Cardiva offers the best solution to current shortcomings in vascular closure procedures and is poised to change the way doctors and hospitals treat their patients.  I am excited for the opportunity to bring this next generation technology to the forefront of patient care and to build a best in class medical device field organization."

About Cardiva Medical, Inc

Cardiva Medical, Inc. is a privately held medical device company that is focused on developing and commercializing innovative vascular closure technology which is designed to help the body heal itself following percutaneous catheterization procedures. Annually, more than 13 million of these percutaneous catheterization procedures worldwide require closure.  Cardiva's VASCADE Vascular Closure System was approved by the FDA in 2013 and approved for CE Marking in Europe in 2012. VASCADE is a new generation extravascular closure device designed to increase the comfort and safety of vascular closure for patients. VASCADE utilizes a unique delivery system based on a proprietary collapsible disc technology that provides temporary hemostasis during the procedure which eliminates the need for an intravascular component. Secure and rapid hemostasis is achieved with VASCADE by the deployment of a thrombogenic resorbable collagen patch at the arteriotomy of the femoral artery. Cardiva's first product line, Catalyst, is a manual compression assist device that has been used in over 400,000 procedures since launch in 2005.

Cardiva Catalyst® and VASCADE® are registered trademarks of Cardiva Medical, Inc.

For additional information about Cardiva, please visit our website at www.cardivamedical.com.

Media Contact:
Malcolm Farnsworth
Chief Financial Officer
Cardiva Medical, Inc.
Phone: 650-388-8555
[email protected]

SOURCE Cardiva Medical